Data investigation

The Dose That Stopped Helping

ACHIEVE-5 tested three doses of oral orforglipron on top of insulin in 546 adults with long-standing type 2 diabetes. Blood sugar improved at every dose, and the top dose was not better than the middle one.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

ACHIEVE-5 tested three doses of oral orforglipron on top of insulin in 546 adults with long-standing type 2 diabetes. Blood sugar improved at every dose, but the top dose was not better than the middle one.[1] Tripling from 12 mg to 36 mg bought nothing on HbA1c, which is not what the word “higher” leads people to expect. Orforglipron’s trial against dapagliflozin found the same pattern at 36 mg.

The middle row

ACHIEVE-5 at 40 weeks, added to titrated insulin glargine.[1]
DoseHbA1c changevs placebo (95% CI)Weight change
Orforglipron 3 mg−1.58%−0.78% (−1.02 to −0.55)−2.6%
Orforglipron 12 mg−1.88%−1.08% (−1.33 to −0.83)−4.8%
Orforglipron 36 mg−1.82%−1.03% (−1.28 to −0.77)−5.4%
Placebo−0.79%—+0.2%

Every dose beat placebo at P<0.001, and the confidence intervals for 12 mg and 36 mg overlap almost entirely. On blood sugar, the effect has reached a ceiling somewhere between 3 and 12 mg, and going higher does not move it.

The two endpoints stop responding at different doses.

Weight kept falling as the dose rose: 2.6%, then 4.8%, then 5.4%. So the same drug shows a plateau on one outcome and a continuing gradient on another. Anyone reasoning that a higher dose is simply a stronger version of the same thing has the wrong model, and the dose that is right depends on which problem is being treated.

Who was in this trial

Median duration of diabetes: 14.6 years. Everyone was on insulin. Mean HbA1c 8.50%. This is the difficult end of type 2 diabetes. These are people whose pancreatic function has been declining for over a decade and who already need injected insulin to manage it.

That context changes how the numbers should be read. We recently covered a trial of a different drug in people managing diabetes with diet and exercise alone, a median of 2.5 years from diagnosis, which posted an HbA1c reduction of 1.94% (retatrutide’s phase 3). The figures look comparable. The populations are not remotely comparable, and we are not setting them against each other.

Achieving nearly two points of HbA1c reduction alongside titrated insulin, fourteen years in, is a harder thing than achieving the same reduction in someone recently diagnosed and taking nothing. Not all of that fall is the drug’s. The placebo group, whose insulin was titrated too, fell 0.79 points, so the drug’s own share was 1.08.[1]

Why the weight number looks small

A 5.4% reduction at the top dose is far below what orforglipron produced in obesity trials, and that is expected rather than disappointing. Insulin causes weight gain, and the placebo group here gained 0.2% while having their insulin titrated upward. The drug was working against that.

Reading this figure against an obesity trial would be a category error of the kind this register documents regularly. Different population, different concurrent treatment, different question. Orforglipron’s obesity results are covered in ATTAIN-2.

What it is good for

  • It answers a real clinical question. Someone on insulin whose blood sugar is still too high has limited options, and adding an oral drug rather than more injections is a meaningful one.
  • Completion was high (507 of 546, or 92.9%), which is a good sign for tolerability in a 40-week trial.
  • The ceiling is practically useful. If 12 mg does what 36 mg does for blood sugar, the higher dose earns its place only through the extra weight effect, which is a different trade to weigh.
  • Forty weeks is short for a condition managed over decades, and this trial reports no cardiovascular or kidney outcomes.

Whether a higher dose costs more is a separate question from whether it works better, and for cash buyers of compounded semaglutide or tirzepatide (not orforglipron, which is not compounded) the answer depends on the seller. Center for Medical Weight Loss (CMWL), LevelsRx and Luci charge one price at every dose. So does Better U Care, which also handles brand-name prescriptions as a separate appointment.

Some flat-priced sellers attach conditions. tru Weight Loss and Aspen both require a three-month commitment, and tru includes lab work in its fee. Loop Health sells only microdosed GLP-1s, while Superior Remedies offers a microdose protocol beside its standard plans. Rese Wellness holds its price at every dose too, but every patient starts with a three-month program paid in a single charge; after that, months are bought one at a time with no subscription. With pricing like this, a step up costs nothing extra, so the decision comes back to the trade this trial describes.

Frequently Asked Questions

Yes. In 546 adults with long-standing type 2 diabetes on insulin glargine, HbA1c fell 1.58% to 1.88% depending on dose against 0.79% on placebo, with every dose superior at P<0.001.
Not for blood sugar. The 36 mg dose produced 1.82% against 12 mg's 1.88%, with overlapping confidence intervals. The effect had reached a ceiling. Weight loss did keep increasing with dose, from 4.8% to 5.4%.
Because everyone was on insulin, which causes weight gain, and their insulin was being titrated upward during the trial. The placebo group gained 0.2%. The drug was working against that, which an obesity trial is not.
Median diabetes duration was 14.6 years, everyone was on insulin, and mean HbA1c was 8.50%. This is the end of the disease where treatments generally perform worst.
Anything about cardiovascular or kidney outcomes, or about durability past 40 weeks in a condition managed across decades.

References

  1. 1.Giorgino F, D'Souza S, Ludwig L, et al. Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial JAMA. 2026. PMID: 42251769.

The Top Dose Keeps Not Being Worth It

Orforglipron beat an SGLT2 inhibitor on blood sugar and lost badly on tolerability: one in five stopped taking it. And its top dose is the third in a row, across three trials, to buy almost nothing.

7 min read

An Oral Pill in a Diabetes Population

Over 72 weeks a daily tablet took 9.6% off the scale for people carrying obesity alongside type 2 diabetes. Why we will not set that figure beside the injectable trials.

7 min read

The Statistic That Asks If Groups Differ

A SOUL secondary analysis found oral semaglutide cutting heart-failure events in people who had heart failure and doing nothing in those who did not. The test of whether that split is real came out at P = .06.

7 min read

The First Pill-Versus-Pill Trial

Orforglipron beat oral semaglutide on HbA1c at every dose pairing in 1,698 adults, and produced twice the dropouts and three times the heart rate rise. Both halves are the result.

8 min read

Rybelsus for Weight Loss: How Much Weight People Lose, and Why It's Less

Rybelsus is approved for type 2 diabetes, not weight. In its trials the 14 mg dose took off 3.1 to 4.4 kg in 26 weeks. Why the Wegovy pill does far more, what is known in people without diabetes, and why insurers won't cover it for weight.

10 min read

Comparing Trials That Never Met

We refused a cross-trial comparison in an earlier article. This article runs the methodologically proper version of it, and explains why it appears to contradict a head-to-head trial without actually doing so.

7 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.1

Direct Meds

Compounded semaglutide at $249/month

8.2

HealthRX

Compounded semaglutide at $165/month after a $99 first month

8.2

bmiMD

Starting below a standard dose, with microdose tiers

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →